Acumen Pharmaceuticals (ABOS) Other Gross PP&E Adjustments (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Other Gross PP&E Adjustments of -$106000.0 in Q1 2026, up 97.55% quarter-over-quarter from -$4.3 million in Q4 2025, and up 55.08% year-over-year from -$68349.7 in Q1 2025.
Acumen Pharmaceuticals' Other Gross PP&E Adjustments history runs 7 years deep, the most recent figure standing at -$106000.0 for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments rose 55.08% year-over-year to -$106000.0; the TTM figure through Mar 2026 stood at -$106000.0 (up 55.08% YoY), while the FY2025 annual figure was -$4.3 million, down 25.66% from the prior year.
- Other Gross PP&E Adjustments came in at -$106000.0 for Q1 2026 at Acumen Pharmaceuticals, up from -$4.3 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$2000.0 in Q3 2023 to a low of -$4.3 million in Q4 2025.
- A 5-year average of -$768176.5 and a median of -$205000.0 in 2025 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments jumped 98.5% in 2023 and plunged 14700.0% in 2024, its largest moves.
- Acumen Pharmaceuticals' Other Gross PP&E Adjustments stood at -$780000.0 in 2022, then slumped by 185.9% to -$2.2 million in 2023, then tumbled by 54.13% to -$3.4 million in 2024, then decreased by 25.66% to -$4.3 million in 2025, then jumped by 97.55% to -$106000.0 in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$106000.0, -$4.3 million, and -$173000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -106,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -106,000.00 |
| Mar 31, 2026 | -106,000.00 |
| Dec 31, 2025 | -4.32 Mn |
| Dec 31, 2025 | -4.32 Mn |
| Sep 30, 2025 | -173,000.00 |
| Sep 30, 2025 | -173,000.00 |
| Jun 30, 2025 | -205,000.00 |
| Jun 30, 2025 | -205,000.00 |
| Mar 31, 2025 | -236,000.00 |
| Mar 31, 2025 | -236,000.00 |
| Dec 31, 2024 | -3.44 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Sep 30, 2024 | -296,000.00 |
| Sep 30, 2024 | -296,000.00 |
| Jun 30, 2024 | -325,000.00 |
| Jun 30, 2024 | -325,000.00 |
| Mar 31, 2024 | -353,000.00 |
| Mar 31, 2024 | -353,000.00 |
| Dec 31, 2023 | -2.23 Mn |
| Dec 31, 2023 | -2.23 Mn |
| Sep 30, 2023 | -2,000.00 |
| Sep 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -29,000.00 |
| Jun 30, 2023 | -29,000.00 |
| Mar 31, 2023 | -67,000.00 |
| Mar 31, 2023 | -67,000.00 |
| Dec 31, 2022 | -780,000.00 |
| Dec 31, 2022 | -780,000.00 |
| Sep 30, 2022 | -133,000.00 |
| Sep 30, 2022 | -133,000.00 |
| Jun 30, 2022 | -167,000.00 |
| Jun 30, 2022 | -167,000.00 |
| Mar 31, 2022 | -201,000.00 |
| Mar 31, 2022 | -201,000.00 |
| Dec 31, 2021 | -263,000.00 |
| Dec 31, 2021 | -263,000.00 |
| Dec 31, 2020 | -85,000.00 |
| Dec 31, 2020 | -85,000.00 |